Literature DB >> 27536360

The two sides of the coin: Similarities and differences in the pathomechanisms of fistulas and stricture formations in irritable bowel disease.

Michael Scharl1, Ramona S Bruckner1, Gerhard Rogler1.   

Abstract

Fistulas and fibrosis or strictures represent frequent complications in irritable bowel disease (IBD) patients. To date, treatment options for fistulas are limited and surgery is often required. Similarly, no preventive treatment for fibrosis and stricture formation has been established. Frequently, stricture formation and fibrosis precede fistula formation, indicating that both processes may be connected or interrelated. Knowledge about the pathology of both processes is limited. A crucial role for the epithelial-to-mesenchymal transition (EMT) in fistula development has been demonstrated. Of note, EMT also plays a major role in the pathogenesis of fibrosis in many organs, and most likely also plays that role in the intestine. In addition, aberrant matrix remodeling, as well as soluble factors such as tumor necrosis factor (TNF), interleukin 13 (IL-13) and tumor growth factor beta (TGFβ) were involved, both in the onset of the fistula and fibrosis formation. Both fistulas and fibrosis may occur due to deregulated wound healing mechanisms from chronic and severe intestinal inflammation; however, further research is required to obtain a better understanding of the complex pathophysiology of fistula and intestinal fibrosis formation, to allow the development of new and more effective preventive treatment options for those important disease complications.

Entities:  

Keywords:  Epithelial-mesenchymal transition; fibrosis; fistula; interleukin 13; irritable bowel disease; metalloproteinase; tumor growth factor beta; wound healing

Year:  2016        PMID: 27536360      PMCID: PMC4971795          DOI: 10.1177/2050640616635957

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  48 in total

Review 1.  AGA technical review on perianal Crohn's disease.

Authors:  William J Sandborn; Victor W Fazio; Brian G Feagan; Stephen B Hanauer
Journal:  Gastroenterology       Date:  2003-11       Impact factor: 22.682

2.  Potential role for SNAIL family transcription factors in the etiology of Crohn's disease-associated fistulae.

Authors:  Michael Scharl; Achim Weber; Alois Fürst; Stefan Farkas; Ekkehard Jehle; Theresa Pesch; Silvia Kellermeier; Michael Fried; Gerhard Rogler
Journal:  Inflamm Bowel Dis       Date:  2010-12-03       Impact factor: 5.325

3.  Interleukin-13 and transforming growth factor β synergise in the pathogenesis of human intestinal fistulae.

Authors:  Michael Scharl; Sandra Frei; Theresa Pesch; Silvia Kellermeier; Joba Arikkat; Pascal Frei; Michael Fried; Achim Weber; Ekkehard Jehle; Anne Rühl; Gerhard Rogler
Journal:  Gut       Date:  2012-01-27       Impact factor: 23.059

4.  CD4+CD161+ T lymphocytes infiltrate Crohn's disease-associated perianal fistulas and are reduced by anti-TNF-α local therapy.

Authors:  Laura Maggi; Manuela Capone; Francesco Giudici; Veronica Santarlasci; Valentina Querci; Francesco Liotta; Ferdinando Ficari; Enrico Maggi; Francesco Tonelli; Francesco Annunziato; Lorenzo Cosmi
Journal:  Int Arch Allergy Immunol       Date:  2012-12-15       Impact factor: 2.749

Review 5.  Pathophysiology of fistula formation in Crohn's disease.

Authors:  Michael Scharl; Gerhard Rogler
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

6.  Long-term success rate after surgical treatment of anorectal and rectovaginal fistulas in Crohn's disease.

Authors:  Thorsten Löffler; Thilo Welsch; Stefanie Mühl; Ulf Hinz; Jan Schmidt; Peter Kienle
Journal:  Int J Colorectal Dis       Date:  2009-01-27       Impact factor: 2.571

7.  Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease.

Authors:  T Kirkegaard; A Hansen; E Bruun; J Brynskov
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 8.  Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD.

Authors:  Giovanni Latella; Gerhard Rogler; Giorgos Bamias; Christine Breynaert; Jon Florholmen; Gianluca Pellino; Shimon Reif; Silvia Speca; Ian C Lawrance
Journal:  J Crohns Colitis       Date:  2014-04-14       Impact factor: 9.071

Review 9.  The gut microbiome in intestinal fibrosis: environmental protector or provocateur?

Authors:  Florian Rieder
Journal:  Sci Transl Med       Date:  2013-06-19       Impact factor: 17.956

10.  The role for dickkopf-homolog-1 in the pathogenesis of Crohn's disease-associated fistulae.

Authors:  Sandra Michaela Frei; Colette Hemsley; Theresa Pesch; Silvia Lang; Achim Weber; Ekkehard Jehle; Anne Rühl; Michael Fried; Gerhard Rogler; Michael Scharl
Journal:  PLoS One       Date:  2013-11-08       Impact factor: 3.240

View more
  5 in total

1.  IL-17A Promotes Initiation and Development of Intestinal Fibrosis Through EMT.

Authors:  Hui-Jing Zhang; Yi-Ning Zhang; Huan Zhou; Lin Guan; Yue Li; Ming-Jun Sun
Journal:  Dig Dis Sci       Date:  2018-08-10       Impact factor: 3.199

Review 2.  A case report of spontaneous umbilical enterocutaneous fistula resulting from an incarcerated Richter's hernia, with a brief literature review.

Authors:  Wei Chen; Lei Liu; Hui Huang; Mianxu Jiang; Tao Zhang
Journal:  BMC Surg       Date:  2017-02-13       Impact factor: 2.102

3.  Succinate Activates EMT in Intestinal Epithelial Cells through SUCNR1: A Novel Protagonist in Fistula Development.

Authors:  Dolores Ortiz-Masiá; Laura Gisbert-Ferrándiz; Cristina Bauset; Sandra Coll; Céline Mamie; Michael Scharl; Juan V Esplugues; Rafael Alós; Francisco Navarro; Jesús Cosín-Roger; María D Barrachina; Sara Calatayud
Journal:  Cells       Date:  2020-04-29       Impact factor: 6.600

4.  Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease.

Authors:  W T van Haaften; J H Mortensen; M A Karsdal; A C Bay-Jensen; G Dijkstra; P Olinga
Journal:  Aliment Pharmacol Ther       Date:  2017-05-08       Impact factor: 8.171

5.  Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs.

Authors:  Sarah Alrubia; Jialin Mao; Yuan Chen; Jill Barber; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2022-09-03       Impact factor: 5.577

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.